BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32802894)

  • 21. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia.
    Stamatopoulos B; Meuleman N; Haibe-Kains B; Duvillier H; Massy M; Martiat P; Bron D; Lagneaux L
    Clin Chem; 2007 Oct; 53(10):1757-66. PubMed ID: 17702857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.
    Baseggio L; Traverse-Glehen A; Petinataud F; Callet-Bauchu E; Berger F; Ffrench M; Couris CM; Thieblemont C; Morel D; Coiffier B; Salles G; Felman P
    Haematologica; 2010 Apr; 95(4):604-12. PubMed ID: 20015887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.
    Shea LK; Honjo K; Redden DT; Tabengwa E; Li R; Li FJ; Shakhmatov M; Chiorazzi N; Davis RS
    Blood Cancer J; 2019 May; 9(6):47. PubMed ID: 31092813
    [No Abstract]   [Full Text] [Related]  

  • 24. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Raponi S; Ilari C; Della Starza I; Cappelli LV; Cafforio L; Piciocchi A; Arena V; Mariglia P; Mauro FR; Gentile M; Cutrona G; Moia R; Favini C; Morabito F; Rossi D; Gaidano G; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jun; 189(5):853-859. PubMed ID: 32064595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
    Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
    Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells.
    Hashimoto S; Dono M; Wakai M; Allen SL; Lichtman SM; Schulman P; Vinciguerra VP; Ferrarini M; Silver J; Chiorazzi N
    J Exp Med; 1995 Apr; 181(4):1507-17. PubMed ID: 7535340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia.
    Szymańska A; Bojarska-Junak A; Drobiecki A; Tomczak W; Roliński J; Hus M; Hus I
    Arch Immunol Ther Exp (Warsz); 2019 Feb; 67(1):55-65. PubMed ID: 30196472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones.
    Osman A; Gocke CD; Gladstone DE
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):97-99. PubMed ID: 28041846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status.
    Ziolkowska E; Wolowiec D; Karpinski P; Blonski JZ; Lech-Maranda E; Borowiec M; Balcerczak E; Sasiadek M; Robak T; Korycka-Wolowiec A
    Leuk Lymphoma; 2019 Jun; 60(6):1409-1419. PubMed ID: 30187811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.
    Eagle GL; Zhuang J; Jenkins RE; Till KJ; Jithesh PV; Lin K; Johnson GG; Oates M; Park K; Kitteringham NR; Pettitt AR
    Mol Cell Proteomics; 2015 Apr; 14(4):933-45. PubMed ID: 25645933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surface antigen expression and correlation with variable heavy-chain gene mutation status in chronic lymphocytic leukemia.
    Vilpo J; Tobin G; Hulkkonen J; Hurme M; Thunberg U; Sundström C; Vilpo L; Rosenquist R
    Eur J Haematol; 2003 Jan; 70(1):53-9. PubMed ID: 12631259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Hotinski AK; Best OG; Thurgood LA; Lower KM; Kuss BJ
    Br J Haematol; 2021 Feb; 192(3):e77-e81. PubMed ID: 33278845
    [No Abstract]   [Full Text] [Related]  

  • 33. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups.
    MacIntyre DA; Jiménez B; Lewintre EJ; Martín CR; Schäfer H; Ballesteros CG; Mayans JR; Spraul M; García-Conde J; Pineda-Lucena A
    Leukemia; 2010 Apr; 24(4):788-97. PubMed ID: 20090781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.
    Patten PE; Chu CC; Albesiano E; Damle RN; Yan XJ; Kim D; Zhang L; Magli AR; Barrientos J; Kolitz JE; Allen SL; Rai KR; Roa S; Mongini PK; MacCarthy T; Scharff MD; Chiorazzi N
    Blood; 2012 Dec; 120(24):4802-11. PubMed ID: 23071276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
    Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of
    Plešingerová H; Janovská P; Mishra A; Smyčková L; Poppová L; Libra A; Plevová K; Ovesná P; Radová L; Doubek M; Pavlová Š; Pospíšilová Š; Bryja V
    Haematologica; 2018 Feb; 103(2):313-324. PubMed ID: 29122990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
    Bomben R; Dal Bo M; Capello D; Forconi F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Zucchetto A; Bertoni F; Rossi FM; Bulian P; Cattarossi I; Ilariucci F; Sozzi E; Spina V; Zucca E; Degan M; Lauria F; Del Poeta G; Efremov DG; Marasca R; Gaidano G; Gattei V
    Br J Haematol; 2009 Feb; 144(4):492-506. PubMed ID: 19036101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
    Bhoi S; Baliakas P; Cortese D; Mattsson M; Engvall M; Smedby KE; Juliusson G; Sutton LA; Mansouri L
    Haematologica; 2016 Feb; 101(2):e63-5. PubMed ID: 26589911
    [No Abstract]   [Full Text] [Related]  

  • 39. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.
    López-Giral S; Quintana NE; Cabrerizo M; Alfonso-Pérez M; Sala-Valdés M; De Soria VG; Fernández-Rañada JM; Fernández-Ruiz E; Muñoz C
    J Leukoc Biol; 2004 Aug; 76(2):462-71. PubMed ID: 15155773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
    Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
    Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.